$0.89
−4.06%Oct 13, 2026, 10:00 UTC
Immuron Ltd announced that results from its Phase 2 trial of once-daily oral Travelan were published in Scientific Reports; the clinical data had previously been announced on March 7, 2024.
Source:Sep 4, 2026, 10:00 UTC
Immuron Limited announced it has executed an exclusive distribution agreement with Calmino group AB to launch PROIBS in the United States, following its earlier launch of PROIBS in Australia during FY2026.